Drug General Information
Drug ID
D03MOQ
Former ID
DNC014628
Drug Name
1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527275]
Structure
Download
2D MOL

3D MOL

Formula
C22H19ClN2O
Canonical SMILES
C1=CC=C(C=C1)C(=CCNC(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3
InChI
1S/C22H19ClN2O/c23-19-11-13-20(14-12-19)25-22(26)24-16-15-21(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-15H,16H2,(H2,24,25,26)
InChIKey
BVFBYUIDPPDGCS-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Cholecystokinin receptor type A Target Info Inhibitor [527275]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Pancreatic secretion
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 527275J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
Ref 527275J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.